UBS Boosts CVS Target to $100 on Strong Margin Outlook

UBS has lifted its price target for CVS Health (NYSE: CVS) to $100, citing a solid margin recovery and upbeat earnings guidance. The investment bank’s upgrade follows the company’s May 6 earnings release, which saw adjusted earnings per share of $2.57—well above the $2.21 consensus—and a 6.2% revenue rise to $100.4 billion.

Key highlights from the quarter include a 52.6% jump in Aetna’s adjusted operating income to $3.04 billion and a tightening of the medical benefit ratio to 84.6% from 87.3%. Management also raised full‑year adjusted EPS guidance to $7.30–$7.50 and projected operating cash flow of at least $9.5 billion.

The stock, which closed at $86.86 on May 6 after a 7.65% pop, sits near its 52‑week high of $88.63, having rebounded from a low of $56.29. Over the past year, CVS shares have surged 35.88%, and they gained 19.53% in the last month alone.

UBS’s upgrade comes alongside a $100 target from Bank of America, which also maintains a buy rating after the company beat revenue, EBIT, and EPS expectations. Morningstar analyst Julie Utterback raised her fair‑value estimate to $105 following the earnings announcement.

Our own 24/7 Wall St. model assigns a $125.45 target to CVS, reflecting a 90% confidence buy rating. The bull case projects a 63.32% total return, with a peak price of $141.86, while a conservative bear scenario still caps the downside at $103.01.

Risks remain, however. Pharmacy reimbursement pressure is compressing Caremark margins, and health‑services margins could be hit by client price concessions and regulatory drug‑price cuts. FY2025 also saw a $5.7 billion goodwill impairment and $1.22 billion in legacy litigation charges, dragging GAAP EPS to $6.75.

In short, UBS believes CVS’s margin recovery—particularly in Aetna—will support the higher guidance and justify the new target. Investors who expect the medical‑benefit ratio to stay below 86% through year‑end may find the stock attractive, whereas those concerned about pharmacy reimbursement headwinds may prefer to stay on the sidelines.